Bevacizumab accelerates corneal wound healing by inhibiting TGF-β2 expression in alkali-burned mouse cornea

BMB Reports

Volumn 42, Issue 12, 2009, Pages 800-805

  Lee, Sung Ho ^a   Leem, Hyun Sung ^b   Jeong, Seon Mi ^a   Lee, Koonja ^b  

^a Lumieye Genetics Co Ltd   (South Korea)

^b Eulji University   (South Korea)

Author keywords

Alkali burn; Bevacizumab; Cornea; TGF 2; Wound healing

Indexed keywords

MUS;

EID: 77949527093     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2009.42.12.800     Document Type: Article

References (27)

1. Stoltz, R. A., Conners, M. S., Gerritsen, M. E., Abraham, N. G. and Laniado-Schwartzman, M. (1996) Direct stimulation of limbal microvessel endothelial cell proliferation and capillary formation in vitro by a corneal-derived eicosanoid. Am. J. Pathol. 148, 129-139.
2. Cursiefen, C., Cao, J., Chen, L., Liu, Y., Maruyama, K., Jackson, D., Kruse, F. E., Wiegand, S. J., Dana, M. R. and Streilein, J. W. (2004) Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest. Ophthalmol. Vis. Sci. 45, 2666-2673.
3. Casey, R. and Li, W. W. (1997) Factors controlling ocular angiogenesis. Am. J. Ophthalmol. 124, 521-529.
4. Chang, J. H., Gabison, E. E., Kato, T. and Azar, D. T. (2001) Corneal neovascularization. Curr. Opin. Ophthalmol. 12, 242-249.
5. Dawson, D. W., Volpert, O. V., Gillis, P., Crawford, S. E., Xu, H., Benedict, W. and Bouck, N. P. (1999) Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285, 245-248.
6. Zhang, P., Wu, D., Ge, J., Zhu, Z., Feng, G., Yue, T., Lin, J. and Zheng, H. (2003) Experimental inhibition of corneal neovascularization by endostatin gene transfection in vivo. Chin. Med. J. (Engl.) 116, 1869-1874.
7. Ormerod, L. D., Abelson, M. B. and Kenyon, K. R. (1989) Standard models of corneal injury using alkali-immersed filter discs. Invest. Ophthalmol. Vis. Sci. 30, 2148-2153.
8. Ormerod, L. D., Garsd, A., Reddy, C. V., Gomes, S. A., Abelson, M. B. and Kenyon, K. R. (1989) Dynamics of corneal epithelial healing after an alkali burn. A statistical analysis. Invest. Ophthalmol. Vis. Sci. 30, 1784-1793.
9. Chung, J. H. and Fagerholm, P. (1989) Corneal alkali wound healing in the monkey. Acta. Ophthalmol. (Copenh.) 67, 685-693.
10. Ferrara, N., Hillan, K. J. and Novotny, W. (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun. 333, 328-335.
11. Rosenfeld, P. J., Fung, A. E. and Puliafito, C. A. (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic. Surg. Lasers Imaging 36, 336-339.
12. Kao, W. W., Ebert, J., Kao, C. W., Covington, H. and Cintron, C. (1986) Development of monoclonal antibodies recognizing collagenase from rabbit PMN; the presence of this enzyme in ulcerating corneas. Curr. Eye Res. 5, 801-815.
13. Burns, F. R., Gray, R. D. and Paterson, C. A. (1990) Inhibition of alkali-induced corneal ulceration and perforation by a thiol peptide. Invest. Ophthalmol. Vis. Sci. 31,107-114.
14. Manzano, R. P., Peyman, G. A, Khan, P., Carvounis, P. E., Kivilcim, M., Ren, M., Lake, J. C. and Chevez-Barrios, P. (2007) Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br. J. Ophthalmol. 91, 804-807.
15. Moromizato, Y., Stechschulte, S., Miyamoto, K., Murata, T., Tsujikawa, A., Joussen, A. M. and Adamis, A. P. (2000) CD18 and ICAM-1-dependent corneal neovascularization and inflammation after limbal injury. Am. J. Pathol. 157, 1277-1281.
16. Hosseini, H. and Nejabat, M. (2007) A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents. Med. Hypotheses 68, 799-801.
17. Lee, J. Y. and Lee, K. J. (2008) Histological changes on the wound healing process of alkali burned mouse cornea. J. Korean Oph. Opt. Soc. 13, 161-169.
18. Desmouliere, A., Darby, I. A. and Gabbiani, G. (2003) Normal and pathologic soft tissue remodeling: role of the myofibroblast, with special emphasis on liver and kidney fibrosis. Lab. Invest. 83, 1689-1707.
19. Jester, J. V., Huang, J., Petroll, W. M. and Cavanagh, H. D. (2002) TGFbeta induced myofibroblast differentiation of rabbit keratocytes requires synergistic TGFbeta, PDGF and integrin signaling. Exp. Eye Res. 75, 645-657.
20. Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C. and Brown, R. A. (2002) Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat. Rev. Mol. Cell Biol. 3, 349-363.
21. Piek, E., Ju, W. J., Heyer, J., Escalante-Alcalde, D., Stewart, C. L., Weinstein, M., Deng, C., Kucherlapati, R., Bottinger, E. P. and Roberts, A. B. (2001) Functional characterization of transforming growth factor beta signaling in Smad2- and Smad3-deficient fibroblasts. J. Biol. Chem. 276, 19945-19953.
22. Evans, R. A., Tian, Y. C., Steadman, R. and Phillips, A. O. (2003) TGF-beta1-mediated fibroblast-myofibroblast terminal differentiation-the role of Smad proteins. Exp. Cell Res. 282, 90-100.
23. Wilson, S. E., Mohan, R. R., Ambrosio, R., Hong, J. and Lee, J. (2001) The corneal wound healing response: cytokine-mediated interaction of the epithelium, stroma, and inflammatory cells. Prog. Retin. Eye Res. 20, 625-637.
24. Stramer, B. M., Zieske, J. D., Jung, J. C., Austin, J. S. and Fini, M. E. (2003) Molecular mechanisms controlling the fibrotic repair phenotype in cornea: implications for surgical outcomes. Invest. Ophthalmol. Vis. Sci. 44, 4237-4246.
25. Bascom, C. C., Wolfshohl, J. R., Coffey, R. J., Madisen, L., Webb, N. R., Purchio, A. R., Derynck, R. and Moses, H. L. (1989) Complex regulation of transforming growth factor beta 1, beta 2, and beta 3 mRNA expression in mouse fibroblasts and keratinocytes by transforming growth factors beta 1 and beta 2. Mol. Cell Biol. 9, 5508-5515.
26. Dwivedi, D. J., Pontoriero, G. F., Ashery-Padan, R., Sullivan, S., Williams, T. and West-Mays, J. A. (2005) Targeted deletion of AP-2alpha leads to disruption in corneal epithelial cell integrity and defects in the corneal stroma. Invest. Ophthalmol. Vis. Sci. 46, 3623-3630.
27. Yoeruek, E., Ziemssen, F., Henke-Fahle, S., Tatar, O., Tura, A., Grisanti, S., Bartz-Schmidt, K. U. and Szurman, P. (2008) Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta. Ophthalmol. 86, 322-328.